Abstract
In this chapter we describe aspects of the regulations which relate to the environmental risk assessment of those risks to the environment arising from use, storage and disposal of a medicinal product (Fig. 21.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson PO (1990) Chlorofluorocarbons in medicinals. Am J Hosp Pharm 47: 1382–1385
CPMP (Committee for Proprietary Medicinal Products) (1994) Note for Guidance on Environmental Risk Assessment for Human Medicinal Products containing or consisting of GMOs, CPMP/III/5507/94
CPMP (Committee for Proprietary Medicinal Products) (2003) Note for Guidance on Environmental Risk Assessment of Medicinal Products for Human Use, CPMP/SWP/4447/00 (draft, released for consultation, July 2003 )
EU (1998) Official Journal of the European Communities C35512, 20. 11. 1998
EU Commission EU (2000) Official Journal of the European Communities L244/25, 29. 09. 2000
EU Commission EU (2002) Official Journal of the European Communities C193/20, 13.08.2002, EU Commission FDA (US Food and Drug Administration) (1995) Retrospective review of ecotoxicity data submitted in environmental assessments. (available under the Freedom of Information (Act) from Public Docket No. 96N - 0057 )
FDA (US Food and Drug Administration) (1998) Guidance for Industry, Environmental Assessment of Human Drug and Biologics Applications. CMC 6, Revision 1. US Department of Health and Human Services (July 1998 ), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)
Graepel P, Alexander DJ (1991) CFC replacements: safety testing, approval for use in metered dose inhalers. J Aerosol Med 4: 193–200
Olejniczak K (1998) Replacement of chlorofluorocarbons in metered dose inhalers. Preclinical requirements. In: Scheuch G (ed) Aerosole in der Inhalationstherapie II. 2. Waldecker Aerosol-InhalationsSeminar. Dustri-Verlag Dr. Karl Feistle, München-Deisenhofen, pp 35–42
Olejniczak K, Bass R (1991) CFC and replacements in medicinal products. J Aerosol Med 4: 205–209
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Olejniczak, K., Spindler, P. (2004). Environmental Risk Assessment of Medicinal Products for Human Use: Aspects of Its Regulations in the European Union, Canada and United States. In: Kümmerer, K. (eds) Pharmaceuticals in the Environment. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09259-0_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-09259-0_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-09261-3
Online ISBN: 978-3-662-09259-0
eBook Packages: Springer Book Archive